Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Mosher

Family Medicine Albany, OR Doctor of Osteopathy

NPI 1235516071 CMS profile 5706453

2605 Willetta St Sw Ste D1, Albany, OR 97321

Open in the dashboard

General payments

$9,292

503 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Mosher of Albany, OR is reported in the CMS Open Payments database as having received $9,292 across 503 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,417 65
2024 General $1,519 78
2023 General $780 39
2022 General $1,752 96
2021 General $1,998 115
2020 General $1,319 80
2019 General $507 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Mosher
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Daniel Mosher were reported at $1,417. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Daniel Mosher Family Medicine median Middle half National median
2019 $507 $150 $41–$543 $163
2020 $1,319 $120 $32–$415 $114
2021 $1,998 $137 $35–$551 $132
2022 $1,752 $137 $37–$512 $149
2023 $780 $149 $42–$545 $160
2024 $1,519 $156 $44–$560 $164
2025 $1,417 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,279 72 payments
  2. Lilly USA, LLC $1,060 56 payments
  3. Pfizer Inc. $1,016 49 payments
  4. Novo Nordisk Inc $841 52 payments
  5. AbbVie, Inc. $811 48 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $605 32 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $409 20 payments
  8. GlaxoSmithKline, LLC. $372 20 payments
  9. Janssen Pharmaceuticals, Inc $326 19 payments
  10. Amgen Inc. $310 15 payments
  11. Other $2,264 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,268 502 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $923 52 payments
  2. NURTEC ODT Pain $652 29 payments
  3. Ozempic $642 41 payments
  4. ZAVZPRET $576 26 payments
  5. RYBELSUS $495 33 payments
  6. MOUNJARO $419 19 payments
  7. Kerendia $409 20 payments
  8. JARDIANCE $378 21 payments
  9. NURTEC ODT Primary Care $344 19 payments
  10. UBRELVY $295 17 payments
  11. Other $7,258 390 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

291

Median for Family Practice: 1,826

Drug cost

$22,098

Median for Family Practice: $120,094

Branded share of claims

8.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 11 $9,812
Mounjaro Tirzepatide Brand 13 $9,102
Tamsulosin Hcl Generic 24 $472
Levothyroxine Sodium Generic 43 $399
Atorvastatin Calcium Generic 18 $315
Pregabalin Generic 14 $307
Metoprolol Succinate Generic 19 $307
Rosuvastatin Calcium Generic 14 $284
Duloxetine Hcl Generic 14 $224
Losartan Potassium Generic 17 $159

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $154
  • Boehringer Ingelheim Pharmaceuticals, Inc. $101
$255 — —
NURTEC ODT
  • PFIZER INC. $154
$154 — —
ZAVZPRET
  • PFIZER INC. $154
$154 — —
MOUNJARO
  • Lilly USA, LLC $104
$104 13 —
Wegovy
  • Novo Nordisk Inc $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

503 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record